Of these, CST3, MRC1 and COMP levels were found to be significantly down-regulated in all CRC stages in comparison to healthy, whilst the levels of CFD and PON1 were found to be significantly lower in stage I and/or stage II compared to healthy controls. This evidence concerns the gene CFD and colorectal carcinoma.